John Fucci is a Partner at Bios Partners, a biotech venture capital firm based in Fort Worth, TX. Mr. Fucci focuses on diligence and negotiations of new investment opportunities, portfolio company management, and investor relations. Currently, he serves on the board of Lantern Pharma, a New Jersey based clinical-staged precision oncology company. Previously, he was a Vice President at Steelhead Capital Management (SCM), a Fort Worth, TX based family office investing in biotechnology, crypto currency, real estate, energy, consumer packaged goods and early staged venture capital investing. Mr. Fucci double majored in Finance and Entrepreneurial Management at Texas Christian University.

Ms. de la Garza has over five years’ experience in financial and scientific analysis as an analyst at Bios Research and Bios Partners. Ms. de la Garza has developed a strong understanding of healthcare market dynamics and commercial viability therein. She received her Bachelor of Science degree (BS) in Biology from Dallas Baptist University and her Masters of Public Health (MPH) from the UT Health Science Center at Houston with a concentration in epidemiology and global health. She is currently working on her Ph.D. at Dallas Baptist University in Leadership Studies.

Mr. Schwarz has over 17 years of experience in investment management and financial services industries across accounting, operations, and investor relations. Currently, he is CFO/COO of Bios Partners, a biotech venture capital firm based in Fort Worth, Texas. Prior to this, Mr. Schwarz was an Associate Director at Crestline, a $9 billion credit-focused institutional asset manager. Previously, Mr. Schwarz was a Senior Auditor with KPMG, LLP specializing in investment managers. Mr. Schwarz is a graduate of Texas A&M University where he received his B.B.A. in Accounting and M.S. in Finance. In addition, he has been a Certified Public Accountant in the State of Texas since 2004.

Stephen Phillips is the Vice President at Bios Partners. Mr. Phillips focuses on diligence and negotiations of new investment opportunities, portfolio company management, and investor relations. Previously, he was Vice President at Moorea Capital, LLC, a Plano, TX-based family office investing in biotechnology, real estate, and operating companies. Mr. Phillips majored in Management and received his M.B.A. from Dallas Baptist University. While attending DBU, he served as chapter president of the national leadership society, Omicron Delta Kappa.

Dr. Van Treuren joined Bios Partners in 2019. Dr. Van Treuren manages deal flow, leads scientific due diligence on new opportunities, and supports portfolio companies. He currently serves on the board of Bobcat Bio. Dr. Van Treuren has eight years of hands-on laboratory experience which produced a robust knowledge of a wide range of cellular processes. His time in the lab has also yielded a comprehensive and analytical understanding of research methodology, especially within oncology. He earned his Ph.D. in Biomedical Sciences with an emphasis in Cancer Biology from the University of North Texas Health Science Center in Fort Worth, TX.

Blake Pate is Vice President of Investments at Bios Partners where he joined in May 2019. At Bios, Blake focuses on investment due diligence, deal flow, and frequently attends banking conferences and medical meetings. Blake also serves as Vice President of Bios Research, a financial services firm that provides public equity research in the healthcare space tailored to institutional firms. Prior to joining Bios Partners, Blake received his BS in Biology and a business minor in May 2019. He also trained in biostatistics, data analysis, and algorithm development while assisting the HPV Working Group at the Yale University School of Medicine. Most recently, Blake received his Master of Science in Biotechnology with a concentration in Enterprise and Entrepreneurship at Johns Hopkins University. Blake also serves as an advisory board member to the DBU College of Business and is a Network Partner for 2048 Ventures.

Mr. Osborn is a Controller at Bios Partners. Prior to starting with Bios Partners in June of 2019, Mr. Osborn worked as an auditor at KPMG LLP, specializing in private equity and hedge fund accounting. Mr. Osborn received his Master’s degree in Accounting from Abilene Christian University.